Response to ‘Eruptive keratoacanthomas arising in the setting of lichenoid toxicity after patients on antiprogrammed cell death‐1 inhibition with nivolumab’

Publisher： John Wiley & Sons Inc

E-ISSN： 1468-3083|32|2|e61-e62

ISSN： 0926-9959

Source： JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol.32, Iss.2, 2018-02, pp. : e61-e62

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Eruptive keratoacanthomas arising in the setting of lichenoid toxicity after programmed cell death 1 inhibition with nivolumab

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 32, Iss. 2, 2018-02 ,pp. : e58-e59

John Wiley & Sons Inc

Access to resources Recommend Favorite

Eruptive keratoacanthomas secondary to nivolumab immunotherapy

By  

INTERNATIONAL JOURNAL OF DERMATOLOGY, Vol. 57, Iss. 3, 2018-03 ,pp. : e28-e29

John Wiley & Sons Inc

Access to resources Recommend Favorite

CXCR4 inhibition in tumor microenvironment facilitates anti‐programmed death receptor‐1 immunotherapy in sorafenib‐treated hepatocellular carcinoma in mice

By  

HEPATOLOGY, Vol. 61, Iss. 5, 2015-05 ,pp. : 1591-1602

John Wiley & Sons Inc

Access to resources Recommend Favorite

Meta‐Analysis of the Risk of Immune‐Related Adverse Events With Anticytotoxic T‐Lymphocyte‐Associated Antigen 4 and Antiprogrammed Death 1 Therapies

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 103, Iss. 2, 2018-02 ,pp. : 318-331

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dramatic Response of a Metastatic Primary Small-Cell Carcinoma of the Pancreas to a Trial of Immunotherapy with Nivolumab: A Case Report

By  

Case Reports in Oncology, Vol. 10, Iss. 2, 2017-08 ,pp. : 720-725

Karger

Access to resources Recommend Favorite